Lilly’s Oral GLP-1 Therapy Sustains Weight Loss After Injectable Switch in Trial
Eli Lilly and Company has revealed positive results from its Phase 3 ATTAIN-MAINTAIN clinical trial, which assessed the oral GLP-1 therapy, orforglipron. This study involved participants who had previously used injectable weight loss medications, Wegovy or Zepbound, and were switched to orforglipron for weight maintenance over a 52-week period.
Key Findings from the ATTAIN-MAINTAIN Trial
The trial successfully achieved its primary and all significant secondary endpoints, demonstrating orforglipron’s effectiveness in maintaining weight loss when compared to a placebo. On average, participants switching from Wegovy retained nearly all of their weight loss, maintaining a difference of only 0.9 kg after a year. Those transitioning from Zepbound experienced an average difference of 5.0 kg in weight maintenance.
Details of the Study
- Primary Endpoint: Superior maintenance of body weight reduction compared to placebo.
- Participants: Individuals with obesity or those who were overweight and had completed the SURMOUNT-5 trial.
- Duration: 52 weeks of treatment.
- Sample Size: 376 participants across the United States.
- Mode of Administration: Once-daily oral therapy.
Results Overview
| From | Starting Weight (kg) | Weight at Switch (kg) | Weight After 52 Weeks (kg) |
|---|---|---|---|
| Wegovy | 113.5 | 95.0 | 95.9 |
| Zepbound | 115.8 | 90.9 | 95.9 |
Safety Profile of Orforglipron
The safety and tolerability of orforglipron were consistent with earlier studies. Its most common adverse effects included mild-to-moderate gastrointestinal symptoms. Discontinuation rates due to adverse effects were similar between participants taking orforglipron and those on placebo.
Future Implications
If the FDA approves orforglipron for obesity treatment, it could offer a more convenient daily medication option for millions dealing with obesity. “Sustaining weight loss is challenging,” remarked Kenneth Custer, Ph.D. “Orforglipron shows promise in helping individuals maintain their hard-earned weight loss.” Detailed results from the ATTAIN-MAINTAIN trial are expected to be published in a peer-reviewed journal next year.
This new oral therapy highlights Eli Lilly’s commitment to addressing obesity as a chronic disease and advancing treatments to assist those on long-term health journeys.
